Prometheus Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Prometheus Biosciences's estimated annual revenue is currently $2.6M per year.
- Prometheus Biosciences's estimated revenue per employee is $25,098
- Prometheus Biosciences's total funding is $451.8M.
- Prometheus Biosciences's current valuation is $1.4B. (January 2022)
Employee Data
- Prometheus Biosciences has 102 Employees.
- Prometheus Biosciences grew their employee count by 26% last year.
Prometheus Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.8M | 51 | 2% | $53M | N/A |
#2 | $29.6M | 125 | -12% | $110M | N/A |
#3 | $0.4M | 257 | 17% | $236.7M | N/A |
#4 | $21.5M | 114 | -23% | $160M | N/A |
#5 | $3.7M | 21 | 11% | N/A | N/A |
#6 | N/A | 60 | 150% | N/A | N/A |
#7 | $147.3M | 261 | -1% | $192.5M | N/A |
#8 | $16.6M | 88 | -1% | $24.1M | N/A |
#9 | $2.7M | 40 | 18% | N/A | N/A |
#10 | $47.1M | 304 | -3% | N/A | N/A |
What Is Prometheus Biosciences?
Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.
keywords:N/A
$451.8M
Total Funding
102
Number of Employees
$2.6M
Revenue (est)
26%
Employee Growth %
$1.4B
Valuation
N/A
Accelerator
Prometheus Biosciences News
In trading on Monday, shares of Prometheus Biosciences Inc (Symbol: RXDX) crossed below their 200 day moving average of $31.68,...
... Cornerstones Health, and Imedex; and as a consultant or adviser to Boehringer Ingelheim, Gilead Sciences, Prometheus Biosciences, Takeda, UCB Biopharma,...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $33M | 102 | 6% | N/A |
#2 | $32M | 102 | -5% | N/A |
#3 | $669.2M | 102 | 59% | N/A |
#4 | $11.2M | 102 | 7% | N/A |
#5 | $32.5M | 103 | 27% | N/A |
Prometheus Biosciences Executives
| Name | Title |
|---|---|
| Mark McKenna | President & CEO, Board Member |
| Allison Luo | Chief Medical Officer |
| Keith Marshall | Chief Financial Officer |
| Christopher Doughty | Chief Business Officer |
| Olivier Laurent | Chief Scientific Officer and Head of R&D |
| Keith W Marshall | Chief Financial Officer |
| Evan McClure | Chief of Staff & VP, Business Operations |
| Mark Stenhouse | Chief Operating Officer |
| Daria Ursol | Chief Medical Officer |
| Lauren Otsuki | COO |
| Mark McKenna | President & CEO, Board Member |
| Vika Brough | SVP, Finance |
| Noël Kurdi | Vice President of Investor Relations and Communications |
| Vika Brough | SVP of Finance |
| MiRa Huyghe | VP, Clinical Operations |
| Evan McClure | Vice President, Corporate Development & Strategy |
| Chris Doughty | SVP of Corporate Development |
| Noël Kurdi | VP of Investor Relations and Communications |
| Evan McClure | Chief of Staff & VP, Business Operations |
| Deanna Nguyen | Vice President, Clinical Development |